Generated banner for Depmap
Generated logo for Depmap

Depmap

K-DenseCommunityCreated by Kuan-lin HuangDistributed by K-Dense

  • Skill
  • Tool integration
  • Science and research
  • CC-BY-4.0
  • Low risk
  • Has scripts

From the author

Retrieves and analyzes Cancer Dependency Map (DepMap) release data, including CRISPR Chronos gene effects, cancer model annotations, omics biomarkers, and PRISM drug sensitivity. Supports cancer-selective dependency, co-essentiality, and candidate synthetic-lethality analyses with release-aware identifiers and statistical checks.
— the description by Kuan-lin Huang

AutoGineer summary

Written by AutoGineer from the skill’s own files, not by the author

DepMap provides a structured approach to retrieving and analyzing large-scale cancer dependency data, including CRISPR Chronos gene effects, omics biomarkers, and PRISM drug sensitivity screens. The skill facilitates the discovery of release-specific datasets, ensures proper handling of model-level metadata, and provides helper functions for statistical analysis of gene dependencies. It emphasizes rigorous data provenance, requiring users to validate release-specific READMEs, checksums, and identifier mappings to ensure biological relevance and statistical validity in exploratory cancer research.

What it does

  • Retrieves and validates DepMap release metadata and file catalogues.
  • Supports analysis of CRISPR Chronos gene effects and dependency statistics.
  • Enables biomarker association testing using Mann-Whitney screening.
  • Facilitates co-essentiality analysis to identify gene-gene relationships.
  • Provides guidance on integrating PRISM drug sensitivity and omics data.
  • Ensures correct handling of model-level annotations and default entry flags.

When to use it

  • When ranking gene dependencies across specific cancer model cohorts.
  • When investigating potential synthetic-lethality candidates.
  • When comparing gene effect profiles against specific biomarker statuses.
  • When performing co-essentiality analysis to explore functional pathways.
  • When integrating multi-omics data with CRISPR screen results.

Advantages

  • Promotes reproducible analysis through release-aware identifier and checksum tracking.
  • Reduces errors in data joining by enforcing model-level and condition-level mapping.
  • Provides standardized helper functions for common cancer dependency workflows.
  • Encourages rigorous statistical practices by requiring multiple-testing adjustments.
  • Helps navigate the complexity of DepMap's diverse data formats and release versions.

Usage examples

“Find the latest DepMap public release and list its available files.”
The agent fetches the current catalogue, filters for public releases, and displays the available files with their metadata for selection.
“Analyze the dependency profile of KRAS in lung cancer models.”
The agent loads the gene effect matrix, filters for lung lineage models, and calculates the mean dependency score to identify potential vulnerabilities.
“Identify genes that are co-essential with a target gene.”
The agent computes Pearson correlations between the target gene's effect profile and all other genes, returning a ranked list of significant correlates.
“Perform a biomarker scan to find dependencies associated with a specific mutation.”
The agent maps the mutation status to model IDs and runs a Mann-Whitney test to identify genes with significantly different effects in mutant versus wild-type models.

Install

  1. Download the skill as a ZIP:

    https://mp-staging.autogineer.com/agent-skills/k-dense-ai/depmap/download
  2. Unzip it into the cross-client skills folder of your project:

    mkdir -p .agents/skills && unzip depmap.zip -d .agents/skills

Documentation by Kuan-lin Huang

DepMap — Cancer Dependency Map

When to use

Use this skill to rank dependencies in cancer models, compare prespecified biomarker cohorts, inspect co-essentiality, or relate genetic dependencies to PRISM compound response. These analyses generate target and synthetic-lethality hypotheses; they do not establish clinical efficacy, a therapeutic window, or a causal interaction.

DepMap integrates Broad and Sanger CRISPR screens and hosts independent RNAi and drug-screen datasets. Match each question to its assay and pinned release. RNAi DEMETER2 is a different perturbation modality, not an older CRISPR scoring method.

1. Discover a release, then obtain its files

Use DepMap Downloads and the selected release's README and release notes. On review, the live catalogue's latest DepMap Public release was 26Q1, dated 2026-04-01. Rediscover before new work; a release name or expected quarter is not evidence a release is available.

Verified public endpoint

GET https://depmap.org/portal/api/no-captcha/download/files returns a complete CSV catalogue, with no request body, API key, or pagination parameters. Required metadata columns are release, release_date, filename, and md5_hash. The live response also has url: older files can have links, while recent release rows have blank links. All 85 entries for 26Q1 had blank url values at review. Treat availability per row, not per endpoint.

The staff announcement introduced this metadata route in July 2026. The older https://depmap.org/portal/api/download/files catalogue can supply download links but returned an HTML verification page during review, including with HTTP 200. Validate content before parsing. Obtain current files through the portal when verification is required. Refresh expiring signed links immediately before use; do not fabricate storage URLs or assume every new release is on Figshare.

No supported contract was verified for the former /api/gene?gene_id=... or /api/data/gene_dependency examples. Use local release matrices for gene slices. Do not assume a Python package named depmap is an official portal client.

From the skill root, use the bundled helpers:

from scripts.depmap_data import fetch_catalogue, select_file, verify_md5

catalogue = fetch_catalogue()
public = catalogue[catalogue["release"].str.startswith("DepMap Public ")]
print(public[["release", "release_date"]].drop_duplicates()
      .sort_values("release_date", ascending=False).head(12))

# Explicit example pin; inspect discovery output before selecting your release.
release = "DepMap Public 26Q1"
record = select_file(catalogue, release, "CRISPRGeneEffect.csv")
print(record[["release", "filename", "md5_hash"]])
# After obtaining this file from the portal:
# verify_md5("CRISPRGeneEffect.csv", record["md5_hash"])

Save the selected metadata, retrieval date, release citation, local checksum, and README alongside analysis outputs. Record source dataset terms separately from this skill's license; newer release terms differ from older Figshare releases. For a missing published checksum, retain a local SHA-256 and explicitly state that it was not compared with a publisher checksum.

2. Inspect file contracts before joining

The following names were verified in the 26Q1 catalogue. Check that release's README for units and identifier level before treating a file as a numeric matrix.

FileUse and important contract
CRISPRGeneEffect.csvIntegrated, model-level Chronos effects; rows are ModelID, columns preserve Symbol (EntrezID)
CRISPRGeneEffectUncorrected.csvUncorrected effects; not interchangeable with corrected effects
CRISPRGeneDependency.csvRelease-specific dependency statistics; confirm probability/FDR definition and direction in the README
Model.csvModel metadata keyed by ModelID
ModelCondition.csvGrowth/treatment conditions keyed by ModelConditionID, mapping to ModelID
ScreenGeneEffect.csv, ScreenSequenceMap.csv, CRISPRScreenMap.csvScreen-level effects and mappings; multiple screens can belong to one model
OmicsExpressionTPMLogp1HumanProteinCodingGenes.csvExpression output with sequencing/model metadata and default-entry flags; exclude metadata columns from expression calculations
OmicsSomaticMutationsMatrixDamaging.csv, OmicsSomaticMutationsMatrixHotspot.csvDistinct mutation annotations; damaging and hotspot calls answer different biological questions
OmicsCNGeneWGS.csv, OmicsCNGeneMC_WES.csvSeparate WGS/WES copy-number products; do not concatenate as one uniformly processed cohort
PortalOmicsCNGeneLog2.csvTransformed portal copy-number product; establish the exact transform before inversion
OmicsProfiles.csv, Gene.csvOmics provenance/mappings and gene annotations
AchillesScreenQCReport.csv, AchillesSequenceQCReport.csvScreen/sequence QC; apply documented eligibility rules rather than invented universal cutoffs

Current model annotations include CellLineName, OncotreeLineage, OncotreePrimaryDisease, and OncotreeSubtype. Legacy sample_info.csv fields (DepMap_ID, lineage, primary_disease) require an explicit conversion. Model.csv includes models without CRISPR measurements: absence from the effect matrix is not a nondependency score.

Omics may be indexed by SequencingID, ModelConditionID, or ModelID. For a basal model analysis, use the release's IsDefaultEntryForModel == Yes flag, then require one row per ModelID. The condition-level flag IsDefaultEntryForMC answers a different question. Subset the assay/datatype before selecting defaults from a mapping table. Never average repeated conditions or count them as independent models without an explicit scientific design.

See the mapping guide source and metadata definitions.

3. Interpret Chronos and inspect a target

Chronos gene effect is continuous and unbounded. More negative values indicate stronger loss of fitness. In the normalized release matrix, approximately 0 is the nonessential-control anchor and −1 is the common-essential-control anchor; −1 is not a dependency boundary. A filter such as ≤ −0.5 is exploratory, not a p-value, FDR, or probability cutoff. Positive effects may reflect growth advantage or technical noise and need validation.

For binary calls, inspect the selected file's statistic and direction. A high dependency probability and a low FDR are different rules. Do not silently convert between them. Use release-matched positive/negative control lists and QC outputs. See score and QC caveats.

The following local-data examples are illustrative until run against your chosen files. Helper behavior is tested using synthetic fixtures; current bulk matrices were not downloaded during this review.

from scripts.depmap_data import load_gene_effect, load_models, gene_profile

effects = load_gene_effect("CRISPRGeneEffect.csv")
models = load_models("Model.csv")
profile = gene_profile(effects, models, "KRAS (3845)")
print(profile[["CellLineName", "OncotreeLineage", "gene_effect"]].head(20))

# Inspect actual annotation values, then choose an exact cohort.
print(profile["OncotreeLineage"].value_counts())
known = profile.dropna(subset=["OncotreeLineage"])
lung = known.loc[known["OncotreeLineage"].eq("Lung"), "gene_effect"]
other = known.loc[~known["OncotreeLineage"].eq("Lung"), "gene_effect"]
if lung.empty or other.empty:
    raise ValueError("Both cohorts require observed effects and known lineage")
print({"n_lung": len(lung), "n_other": len(other),
       "other_minus_lung_mean": other.mean() - lung.mean(),
       "lung_fraction_below_exploratory_cutoff": (lung <= -0.5).mean()})

This is a descriptive comparison against other cancer models, not against normal tissue. Keep the denominator and missingness counts. Preserve complete gene labels; a symbol can be ambiguous, and the helper refuses ambiguous symbol resolution.

4. Test biomarker associations

  1. Define the alteration before inspecting target scores. A damaging-call matrix does not establish biallelic loss; activating KRAS hotspots require a different definition from generic damaging mutations.

  2. Map profiles to the correct model/condition. Use 0 only for an assayed negative, 1 for the prespecified biomarker, and missing for unknown status.

  3. Restrict to scientifically comparable models (lineage, culture conditions, screen source and related-patient structure). Inspect confounding before testing.

  4. Test every eligible gene in the planned family, then adjust all its p-values before selecting hits. Report group sizes, effect sizes, p-values, and q-values.

  5. Validate candidate synthetic lethality with matched/isogenic perturbations and rescue or orthogonal evidence; association alone is insufficient.

import pandas as pd
from scripts.depmap_data import biomarker_scan

# User-prepared, release-matched annotation after the mapping and curation above.
status = pd.read_csv("curated_biomarker_status.csv", index_col="ModelID")["status"]
results = biomarker_scan(effects, status, min_n=5)
# Positive effect_size means stronger dependency in biomarker-positive models.
candidates = results.loc[(results["qval"] < 0.1) & (results["effect_size"] > 0)]

This one-sided Mann–Whitney screen is exploratory and does not adjust for covariates. min_n=5 is an explicit example floor, not a power guarantee. For inference across lineages, fit an appropriate adjusted model and inspect effect stability within lineages; do not report the helper's q-value as confounder-adjusted.

5. Co-essentiality and drug sensitivity

from scripts.depmap_data import coessentiality

correlates = coessentiality(effects, "KRAS (3845)", min_n=500)
print(correlates[["gene", "n", "r", "pval", "qval"]].head(20))

min_n is configurable and should be prespecified for the analysis. Sparse genes can dominate rankings with spurious correlations; always retain the pairwise sample count. The helper uses pairwise complete observations and skips constant genes. Pearson/BH output still needs lineage, library, and screen-quality checks; co-essentiality is not proof of a physical interaction or shared pathway. The DepMap team's discussion documents this specific sparse-coverage failure mode.

For PRISM, first select the exact screen/release and endpoint. Treatment-info CSVs are annotations, not sensitivity values. The original primary screen's primary-screen-replicate-collapsed-logfold-change.csv has response rows keyed by cell-line row_name and columns keyed by treatment column_name. Join the corresponding cell-line and treatment-info files; retain compound, dose, and screen identity. Lower log2 fold change indicates greater loss of viability. Secondary-screen AUC comes from dose-response curve parameters and is not the same quantity as single-dose log fold change. See the PRISM workflow before loading these files.

Validation and sources

Before reporting: verify release/file identity, unique joins, identifier level, complete gene labels, cohort membership, missingness, screen eligibility, score units/direction, multiple-testing family, and whether evidence is observational. Expression, copy number, and CRISPR can share technical confounders; low expression does not guarantee a measured score of zero. Broad essentiality motivates normal cell/selectivity studies; it does not by itself prove a target is undruggable.

The live no-captcha catalogue and original PRISM READMEs were fetched successfully. The helper uses Python urllib, which succeeded at review; the same public endpoint returned HTTP 403 with a default requests client. Surface access failures instead of treating an error page as data. Protected portal endpoints returned verification pages; authenticated downloads and current-matrix end-to-end analysis remain unverified. This review makes no claim of a working bearer-token API or undocumented gene-query endpoints.

Files

LICENSE

Creative Commons Attribution 4.0 International

 Creative Commons Corporation (“Creative Commons”) is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an “as-is” basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC-licensed material, or material used under an exception or limitation to copyright. More considerations for licensors.

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor’s permission is not necessary for any reason–for example, because of any applicable exception or limitation to copyright–then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public.

Creative Commons Attribution 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 – Definitions.

     a.	Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

     b.	Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

     c.	Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

     d.	Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

     e.	Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

     f.	Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

     g.	Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

     h.	Licensor means the individual(s) or entity(ies) granting rights under this Public License.

     i.	Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

     j.	Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

     k.	You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 – Scope.

     a.	License grant.

          1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

               A. reproduce and Share the Licensed Material, in whole or in part; and

               B. produce, reproduce, and Share Adapted Material.

          2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

          3. Term. The term of this Public License is specified in Section 6(a).

          4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.

          5. Downstream recipients.

               A. Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

               B. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

          6.  No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

          1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

          2. Patent and trademark rights are not licensed under this Public License.

          3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.

Section 3 – License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

     a.	Attribution.

          1. If You Share the Licensed Material (including in modified form), You must:

               A. retain the following if it is supplied by the Licensor with the Licensed Material:

                    i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

                    ii. a copyright notice;

                    iii. a notice that refers to this Public License;

                    iv.	a notice that refers to the disclaimer of warranties;

                    v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

               B. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

               C. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

          2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

          3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

          4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 – Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

     a.	for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database;

     b.	if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

     c.	You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 – Disclaimer of Warranties and Limitation of Liability.

     a.	Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.

     b.	To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.

     c.	The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 – Term and Termination.

     a.	This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

     b.	Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

          1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

          2. upon express reinstatement by the Licensor.

     c.	For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

     d.	For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

     e.	Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 – Other Terms and Conditions.

     a.	The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

     b.	Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 – Interpretation.

     a.	For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

     b.	To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

     c.	No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

     d.	Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark “Creative Commons” or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.

Requirements and compatibility

Works with: Claude Code, Claude apps, OpenAI Codex, GitHub Copilot, Cursor, Gemini CLI, Kiro, OpenCode, Goose, Amp, Roo Code, JetBrains Junie, Factory Droid, Devin (ex-Windsurf), Mistral Vibe, OpenHands, Letta

“Works with” means the tool reads the open Agent Skills format; a skill written for one tool may use features others lack.

Needs: Needs an API key, Needs Python

The author says: Requires Python 3.10+ with numpy, pandas, and scipy>=1.11 for the bundled helpers. Network access is needed for release discovery; downloading current data may require browser verification through the DepMap portal.

Security

What our scanner noticed· Low risk

  • Scripts that your agent may run

This skill includes scripts that your agent may run. Read them before you use it.

A static scan is not a guarantee. Skills are third-party content: review a skill before you let an agent use it.

Attribution and licence

Created by
Kuan-lin Huang
Publisher
K-Dense (Community)
Distributed by
K-Dense
Source
K-Dense-AI/scientific-agent-skills · skills/depmap · commit a25cf9e
Licence
Creative Commons Attribution 4.0 International (redistribution allowed)
  • LICENSE (written by AutoGineer)
  • ATTRIBUTION.md (written by AutoGineer)
Synced

AutoGineer is not affiliated with or endorsed by Kuan-lin Huang or K-Dense.

Download ZIP

The ZIP holds the skill’s files, its licence files and an ATTRIBUTION.md. Download depmap.zip